56
Participants
Start Date
April 12, 2018
Primary Completion Date
February 2, 2022
Study Completion Date
February 2, 2022
Melphalan flufenamide (Melflufen)
Intravenous infusion
Dexamethasone
Oral tablets
Bortezomib
Subcutaneous administration
Daratumumab
Intravenous infusion
The Ohio State University, Columbus
Dana Farber Cancer Institute, Boston
Fakultní nemocnice Brno, Brno
Fakultní nemocnice Hradec Králové, Hradec Králové
Fakultní nemocnice Ostrava, Ostrava
Všeobecná fakultní nemocnice, Prague
Hôpital Morvan, Brest
Centre Jean Bernard - Clinique Victor Hugo, Le Mans
Hôpital privé du Confluent, Nantes
Centre Hospitalier Lyon Sud, Pierre-Bénite
Centre Hospitalier Universitaire Institut Gustave Roussy, Villejuif
Hospital Universitai Germans Trias i Pujol, Badalona
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital Universitario 12 de Octubre, Madrid
Complejo Hospitalario de Salamanca, Salamanca
Hospital Universitario Marques de Valdecilla, Santander
Lead Sponsor
Oncopeptides AB
INDUSTRY